Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?
- 1 January 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet Oncology
- Vol. 21 (1), 21-24
- https://doi.org/10.1016/s1470-2045(19)30792-2
Abstract
No abstract availableFunding Information
- Associazione Italiana per la Ricerca sul Cancro, Investigator (19174)
This publication has 10 references indexed in Scilit:
- Treatment sequencing in oncology: balancing clinical trial and real-world evidence ForewordFuture Oncology, 2019
- Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic ReviewJNCI Cancer Spectrum, 2018
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 2018
- Factors Associated With Attrition in a Multicenter Longitudinal Observational Study of Patients With Advanced CancerJournal of Pain and Symptom Management, 2017
- Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99Annals Of Oncology, 2016
- Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of TherapyJournal of the National Comprehensive Cancer Network, 2014
- Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX TrialClinical Breast Cancer, 2011
- Erratum: Global Cancer StatisticsCA: A Cancer Journal for Clinicians, 2011
- Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial GroupBreast Cancer Research and Treatment, 2009
- Characteristics and implications of attrition in health-related quality of life studies in palliative carePalliative Medicine, 2009